PD-1 and PD-L1 blockade in gastrointestinal malignancies

被引：81
|
作者：
Lote, Hazel
Cafferkey, Catherine
Chau, Ian [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England
来源：
CANCER TREATMENT REVIEWS | 2015年 / 41卷 / 10期
关键词：
Programmed death; PD-1; PD-L1; Gastrointestinal cancer; Immunotherapy; Immune checkpoint blockade; TUMOR-INFILTRATING LYMPHOCYTES; CLINICAL-SIGNIFICANCE; ANTI-PD-L1; ANTIBODY; CHECKPOINT BLOCKADE; ANTITUMOR IMMUNITY; CANCER; B7-H1; IPILIMUMAB; EXPRESSION; HEPATITIS;
D O I：
10.1016/j.ctrv.2015.09.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy represents a major breakthrough in cancer therapy in recent years. Immune-checkpoint blockade using PD-1 and PD-L1 antibodies appears to be one of the most promising immunotherapy approaches. Immunotherapy differs from conventional cancer treatment because of its ability to produce durable responses in some patients. In this review article, we explore the available evidence and summarise current clinical trials for PD-1 and PD-L1 blockade in gastrointestinal malignancies. The challenge now is to develop strategies to increase the efficacy of PD-1 and PD-L1 blockade in gastrointestinal cancer patients, such as combination therapy with chemotherapy, radiotherapy or other immunotherapy, along with validating biomarkers to select patients and personalise treatment. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：893 / 903
页数：11
相关论文
共 50 条
  • [1] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    [J]. ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [2] Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
    Chen, Meng
    Li, Chenyan
    Sun, Mingjun
    Li, Yiling
    Sun, Xuren
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [3] Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Nowicki, Theodore S.
    Hu-Lieskovan, Siwen
    Ribas, Antoni
    [J]. CANCER JOURNAL, 2018, 24 (01): : 47 - 53
  • [4] Toxicities Associated With PD-1/PD-L1 Blockade
    Wang, Daniel Y.
    Johnson, Douglas B.
    Davis, Elizabeth J.
    [J]. CANCER JOURNAL, 2018, 24 (01): : 36 - 40
  • [5] PD-1/PD-L1 checkpoint in hematological malignancies
    Annibali, O.
    Crescenzi, A.
    Tomarchio, V.
    Pagano, A.
    Bianchi, A.
    Grifoni, A.
    Avvisati, G.
    [J]. LEUKEMIA RESEARCH, 2018, 67 : 45 - 55
  • [6] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    [J]. JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [7] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Wang, Dongxu
    Lin, Jianzhen
    Yang, Xu
    Long, Junyu
    Bai, Yi
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Seery, Samuel
    Zhao, Haitao
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [8] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Dongxu Wang
    Jianzhen Lin
    Xu Yang
    Junyu Long
    Yi Bai
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Samuel Seery
    Haitao Zhao
    [J]. Journal of Hematology & Oncology, 12
  • [9] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
  • [10] PD-1/PD-L1 Blockade Enhances the Efficacy of Imatinib in Gastrointestinal Stromal Tumor (GIST)
    Seifert, Adrian M.
    Kim, Teresa S.
    Greer, Jonathan B.
    Cohen, Noah A.
    Beckman, Michael J.
    Santamaria-Barria, Juan A.
    Zeng, Shan
    Crawley, Megan H.
    Green, Benjamin L.
    DeMatteo, Ronald P.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (03) : S129 - S129
12345